Pacific Edge traded at 0.68 this Friday July 1st, decreasing 0 or 0 percent since the previous trading session. Looking back, over the last four weeks, Pacific Edge lost 16.05 percent. Over the last 12 months, its price fell by 44.26 percent. Looking ahead, we forecast Pacific Edge to be priced at 0.67 by the end of this quarter and at 0.63 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Avita Therapeutics Inc 1.44 0.05 3.60% -73.58%
Opthea Ltd 1.20 0.10 8.64% -6.27%
Paradigm Biopharmaceuticals Ltd 0.96 -0.01 -1.04% -54.09%
Pacific Edge 0.68 0 0% -44.26%
PYC Therapeutics Ltd 0.07 0.001 1.54% -56.00%
Telix Pharmaceuticals Ltd 4.64 0.11 2.43% -20.14%

Indexes Price Day Year
NZX 50 10753 -115.54 -1.06% -15.41%

Pacific Edge
Pacific Edge Limited is a cancer diagnostics company. The Company develops and commercializes diagnostic and prognostic tools for the early detection and management of cancers. The Company's segments include NZ Laboratory, US Laboratory and Research NZ & Australia. Its segments are engaged in the research and development of diagnostic and prognostic products for human cancer both in New Zealand and Australia, and operation of the laboratories used for the detection of bladder cancer in the United States and New Zealand. It offers Cxbladder, which is a suite of non-invasive laboratory tests for the detection and the management of bladder cancer. Cxbladder includes a suite of urine-based molecular tests to determine the likelihood of bladder cancer in patients presenting with hematuria. Its pipeline includes Cxcolorectal, which is a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancer, enabling prediction of aggressiveness of the tumor.